title: [A case of locally advanced rectal cancer had a pathological complete response to XELOX Therapy].
abstract: The patient was a 62-year-old man with bowel obstruction in a locally advanced rectal cancer. Computed tomography (CT) scan of the abdomen showed tumor enlargement(11.4 × 9.0 cm)that invaded the urinary bladder, but no distant metastasis. XELOX therapy was planned in order to shrink or eliminate the tumor after a sigmoid colostomy. Four courses of XELOX therapy were perfomed. Consequently, the level of the tumor marker had been restored to a normal range. CT scan revealed marked shrinkage of the tumor (6.1 × 5.2 cm) and a sharply-defined border between the tumor and the urinary bladder. Three weeks after chemotherapy, a low anterior resection as a radical surgery, and a temporary ileostomy were performed. The post-operative course was good. The histological effect was judged to be grade 3. There were no viable cancer cells in the rectal tumor and lymph nodes. The patient is alive and has been disease-free for 10 months after the operation. XELOX therapy as pre-operative chemotherapy might be safe and effective for patients with locally advanced rectal cancer.
authors.affiliation: Division of Surgery,Nagaoka Chuo General Hospital.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tonoike
authors.forename: Mikako
authors.initials: M
authors.lastname: Kawahara
authors.forename: Shigeto
authors.initials: S
authors.lastname: Makino
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nishimura
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kawachi
authors.forename: Keiya
authors.initials: K
authors.lastname: Nikkuni
authors.forename: Akito
authors.initials: A
authors.lastname: Sato
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Fukuhara
authors.forename: Shoji
authors.initials: S
authors.lastname: Watanabe
authors.forename: Tomomi
authors.initials: T
authors.lastname: Sato
authors.forename: Takashi
authors.initials: T
authors.lastname: Tomidokoro
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ikarashi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D002272:Carcinoembryonic Antigen / Q000097:blood; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010071:Oxaloacetates; D012004:Rectal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D002272:Carcinoembryonic Antigen; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil